Navigation Links
Onyx Pharmaceuticals Reports First Quarter 2011 Financial Results
Date:5/4/2011

)Net loss per share:Basic$
(0.78)$
(0.19)Diluted (4)$
(0.78)$
(0.19)Computation of diluted shares:Basic 63,00862,353Dilutive effect of options--Diluted (4)63,00862,353(1)  Includes employee stock-based compensation charges of:Research and development$
926$
912Selling, general, and administrative4,4294,030Total employee stock-based compensation$
5,355$
4,942(2)
Includes a $12.7 million non-cash expense related to the unamortized balance of funding provided to S*BIO in May 2010.

(3) Includes a $3.0 million impairment charge which reflects the reassessment of the fair value of Onyx's equity investment in S*BIO.

(4) Under the "if-converted" method, interest and issuance costs and potential common shares related to the Company's convertible senior notes were excluded in the computation of diluted per share amounts for the three months ended March 31, 2011 and 2010 because their effect would be anti-dilutive. ONYX PHARMACEUTICALS, INC.CALCULATION OF REVENUE FROM COLLABORATION AGREEMENT(In thousands, unaudited)Three Months EndedMarch 31, 20112010Nexavar product revenue, net (as recorded by Bayer)$ 235,467$ 214,361Nexavar revenue subject to profit sharing (as recorded by Bayer)$ 193,170$ 185,867Combined cost of goods sold, distribution, selling, general and administrative expenses74,01075,698Combined collaboration commercial profit$ 119,160$ 110,169Onyx's share of collaboration commercial profit$   59,580$   55,084Reimbursement of Onyx's shared marketing expenses4,6045,824Royalty revenue2,9611,995Revenue from collaboration agreement$   67,145$   62,903ONYX PHARMACEUTICALS, INC.RECONCILIATION OF GAAP TO NON-GAAP NET LOSS(In thousands, except per share amounts)(unaudited)Three Months EndedMarch 31, 20112010GAAP net loss$(49,162)$(12,044)Non-GAAP adjustments:Contingent consideration11,4953,448Employee stock-based compensation5,3554,942Imputed interest related to the conver
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced today ... been enrolled into the Company,s Phase 2 clinical trial. ... of Gem,s lead compound, GPX-150 (an investigational medication), in ... metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... Colo. , Jan. 22, 2015  BiOptix is pleased ... as Vice President of Chemistry and Biochemistry. Scott joins ... Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course of ... development. "Scott is a nationally recognized thought ...
(Date:1/22/2015)... , Jan. 22, 2015  Amgen (NASDAQ: AMGN ) ... year 2014 financial results on Tuesday, Jan. 27, 2015, after the ... by a conference call with the investment community at 2 p.m. ... A. Bradway , chairman and chief executive officer, and other members ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
... R.I., Oct. 15 CVS/pharmacy announced today that its ... in light of manufacturer delays in delivery of seasonal ... MinuteClinic will continue to administer seasonal flu vaccines at ... season with the supply of vaccine replenished as frequently ...
... Inc. (Nasdaq: CYNO ), a leading developer ... systems, today announced that the company will host its third-quarter ... a.m. ET. , On the call, President and Chief Executive ... Officer Timothy Baker will discuss Cynosure,s financial results, as well ...
Cached Medicine Technology:CVS Caremark Announces Updates to Flu Vaccine Program 2CVS Caremark Announces Updates to Flu Vaccine Program 3Cynosure to Announce Third-Quarter 2009 Financial Results on October 27 2
(Date:1/22/2015)... 22, 2015 The Incredible Bulk is a ... to increase lean muscle by up to 30lbs in less ... attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , ... a step-by-step, scientific diet formula that allows the body to ...
(Date:1/22/2015)... 22, 2015 Blue Cross and Blue Shield ... exemplify what it means to “Live Fearless.” , ... to share their stories about how they or someone they ... others by living in the moment. By telling these types ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The federal court ... the U.S. District Court, Southern District of West Virginia has ... in that proceeding’s first bellwether trial. In an Order dated ... new trial after finding that C.R. Bard had not proven ...
(Date:1/22/2015)... A new white paper by The Beryl Institute ... long-term care environment as well as provides recommendations for ... “The Power of Person-Centeredness in Long-Term Care: A View ... patient, resident and family experience in long-term care and ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Autocarinsurancebest.com has released ... purchasing a commercial auto insurance policy . , Auto ... their vehicles. It is no longer necessary to call an ... are now available online on a single website: http://autocarinsurancebest.com/ ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2
... were bewildered as about 3,000 people in the steel town were ... first reported in a small group at a slum// cluster in ... Monday. Since then, it has rapidly spread to other parts of ... headache and acute colic pain, said a senior district health official. ...
... draw attention to the issue of self harm. Self-Harm is ... that need support, help and above all, understanding. According to ... know how to help a person who self-harms. ... provoking statistics to the fore - that nearly 41% ...
... U.S. government plans to reimburse funds spent on poor ... Centers// for Medicare and Medicaid Services, told a National ... the states to file reimbursement claims for Medicaid recipients ... D Program. ,It also plans to ...
... itself to tackle a crippling disease which is a very ... be spread by mosquitoes// . This fever has already hit ... France. ,According to the French Health Minister, Bertrand, ... population , and many returning to the mainland from the ...
... of the bird flu scare, the Indian Railways has decided ... and has decided to bring back the chicken on its ... the serving of chickens and eggs in any form from ... ministry said in a statement. "It is now safe to ...
... There is heavy import restrictions due to the bird ... established import restrictions, including Japan and Hong Kong temporarily ... to this development World Health Organization publicly stated that ... to ease consumers' fears and concerns. In its statement, ...
Cached Medicine News:
... and 4 metal chest electrodes on ... procedure enabling a patient to easily ... ECG through a simple change of ... per lead and 10 seconds of ...
... IMPACs comprehensive information system designed specifically ... integrate and streamline their diagnostic, management, ... intuitive software solution. Thousands of laboratory ... have proven PowerPaths unique "case-centric model ...
... The Digital-Photo Adapter ... designed optics for the ... technology. In combination with ... this is the best ...
... The CMGS-1 Color Mini-Ganzfeld Stimulator is ... can be integrated with your existing LKC ... with other visual electrodiagnostic test systems. ... is the smallest commercial Ganzfeld to meet ...
Medicine Products: